

ANANDA PHARMA PLC

**Consolidated Interim Financial Statements
(Unaudited)**

Period Ended 31 July 2025

Company registration number: 11159584

Consolidated Interim Financial Statements

Period Ended 31 July 2025

Contents

	Page
Company Information	3
Business Review	4 - 5
Directors' Report	6
Consolidated Interim Statement of Comprehensive Income	7
Consolidated Interim Statement of Financial Position	8
Consolidated Interim Statement of Changes in Equity	9 - 10
Notes to the Consolidated Interim Financial Statements	11 - 14

Company Information

Period Ended 31 July 2025

Company registration number	11159584
Directors	Charles Morgan Melissa Sturgess John Treacy Stuart Piccaver Clive Page Jeremy Sturgess-Smith
Secretary	Shaun Zulafqar
Registered office	Huckletree Bishopsgate 8 Bishopsgate London EC2N 4BQ
Independent auditor	PKF Littlejohn LLP 15 Westferry Circus London E14 4HD
Corporate Adviser & Broker	SP Angel Corporate Finance LLP Prince Frederick House 35-39 Maddox Street London W1S 2PP
Solicitor	Orrick Herrington & Sutcliffe LLP 107 Cheapside London EC2V 6DN

Business Review**Period Ended 31 July 2025**

The Directors present the consolidated interim results of Ananda Pharma Plc ("the Company"), together with its subsidiaries ("the Group") for the period from 1 February 2025 to 31 July 2025.

UPDATE ON OPERATIONS**Corporate**

In February, we appointed Viridian Capital as advisors to the Company. Viridian is a US based investment bank with a long and successful history of mergers, acquisitions and capital raising in the North American cannabis sector. We have identified the US as the main target market both from a funding and a commercial perspective, given its depth in pharmaceuticals and cannabis businesses. Since appointing Viridian we have been working with their president and founder, Scott Greiper, on refining the Ananda story and how we communicate that story to make sure we are properly prepared for the US market activities. To support this US focus and increase corporate visibility, we have had Ananda's shares admitted to trading on the OTC exchange in New York under ticker ANANF.

During the period Chris Tovey, Giles Moss and Andy Rust were also appointed as Advisors. Chris and Giles are both ex-GW Pharma senior executives. Chris, in particular, was part of the GW team which took Epidiolex through Federal Drug Administration ('FDA') and EMA regulatory approvals, was a key driver of GW Pharma's ('GW') IPO onto NASDAQ and its sale to Jazz Pharmaceuticals for USD7.2bn in 2021. Giles was a senior European executive with the group. Together they bring significant expertise in CBD drug development and regulatory approvals as well as experience working for a quoted pharmaceutical company and managing very large and complex transactions. We see them as key resources as MRX1 moves through its clinical development and also as we grow Ananda corporately.

Andy is a veteran of pharmaceutical sales, with specific experience in pain medication sales in the US. His most recent role was as Head of Respiratory at Chiesi Group, where he led the strategic direction of the group's portfolio, helping grow revenues of the respiratory range to over €1.5 billion. Andy is on board to provide long-range strategic thinking for Ananda as we begin to plan in detail our go to market strategy.

MRX1 (Phase 1 Pharmacokinetic study ('PK'), Chemotherapy Induced Peripheral Neuropathy ('CIPN') & Endometriosis)

We have now completed the development work for MRX1. We have gathered the required stability data (2 years), produced the required number of consistent 'trial' manufacturing batches (3) and completed the Dossier that sits alongside MRX1 as an 'Investigational Medicine' ('IM'). This work is required for all IMs ahead of use in a clinical trial/setting. Following completion of this work, we completed the manufacturing of a GMP (Good Manufacturing Practices) batch of MRX1 for use in all three of our MRX1 clinical trials. 40 litres were formulated, representing the first half of the required volume for the CIPN and endometriosis trials and all of the required volume of MRX1 for our Phase 1 study in Australia.

Regarding the Phase 1 study, we delivered the required volume of MRX1 CBD formulation to the trial site in Melbourne, Australia. The Phase 1 trial is designed to give us detailed data on the pharmacokinetic profile of MRX1 including safety, tolerability, food effect and PK of MRX1. PK is the way the body absorbs a drug, how it stays in the body and the rate of excretion. Following the end of the period, we announced that the last participant had completed dosing and that next milestones on this study are 1) confirmation of no adverse events, expected before the end of the year, and 2) the final study report, due in Q1 2026.

As the Phase 1 study ran in Australia, we will be due an R&D tax rebate of up to 43.5% of qualifying expenditure, making it the most cost-effective location to run the trial without sacrificing regulatory robustness - Australian trial data is readily accepted by the FDA and MHRA. The first year's R&D tax return was recently submitted and the cash rebate will be disclosed as part of the next set of Group accounts.

Business Review**Period Ended 31 July 2025**

On CIPN and endometriosis, we have been working with the clinical trial teams to prepare the protocols and supporting documents for trial commencement. We expect to receive ethics approvals for both trials before the end of the year and for recruitment to start shortly thereafter. The timeline of the endometriosis and CIPN trials is independent of the Phase 1 PK study read out and will run concurrently.

To conclude, I have to say that the past year has absolutely flown by, and we have done a huge amount to refine our strategy. The highlight of the period was Ananda transitioning to a clinical stage company which has dosed participants with MRX1 CBD. This is a huge step forward for us and has proved a great learning experience in managing clinical activity. This learning will be invaluable as we move to recruitment and dosing of the first patients in the Phase 2 and 3 trials. In Q1 2026

We do all this because 1 in 10 women suffer from endometriosis and far too many people suffer from chemotherapy induced peripheral neuropathy. Our efforts are designed to help these patients while also delivering returns to our supportive shareholders. It is only possible because we have small but mighty team. Thanks to them we keep kicking the goals that will pay off.

In the period, the Group incurred a loss of £1,954,291 before tax, which solely represents operational costs. Net assets of the Group at the interim point were £295,383.

On behalf of the board

Melissa Sturgess, Chief Executive Officer

13 October 2025

Directors Report**Period Ended 31 July 2025**

The directors present their consolidated interim financial statements of the Group for the period from 1 February 2025 to 31 July 2025.

Directors of the company

The directors who have served during the period and up to the date of approval were as follows:

Charles Morgan
Melissa Sturgess
John Treacy
Stuart Piccaver
Clive Page
Jeremy Sturgess-Smith

Results

The consolidated statement of comprehensive income is set out on page 7 and shows the loss for six-month period to 31 July 2025. The directors consider the loss for the period to be in line with expectations. The directors do not recommend the payment of a dividend.

This report was approved by the Board and signed on its behalf.

Melissa Sturgess, Chief Executive Officer
13 October 2025

Consolidated Interim Statement of Comprehensive Income

Period Ended 31 July 2025

Note		Group 6 months to 31 July 2024		Group Year ended 31 January 2025		Group 6 months to 31 July 2024	
		Unaudited £	Audited £	Unaudited £	Audited £	Unaudited £	Audited £
Revenue		5,135		1,018		764	
Administrative expenses		(1,579,192)		(2,937,081)		(756,938)	
Other external expenses		-		(956)		-	
Impairment		-		-		-	
Depreciation and other amounts written off tangible and intangible assets		(316,981)		(633,966)		(315,808)	
Interest payable		(83,410)		(219,697)		(144,129)	
Interest receivable		20,157		20,195		167	
Loss from operations		(1,954,291)		(3,770,487)		(1,215,944)	
Taxation		-		-		2,697	
Other Comprehensive Income	1						
R&D repayment		-		108,346		-	
Currency translation				984			
Royalties		(12)		-		(23)	
Total loss for the period		(1,954,303)		(3,661,157)		(1,213,270)	
Earnings per share							
Basic and diluted earnings per share (pence)	2		(0.05p)		(0.10p)		(0.04p)

There was no other comprehensive income in the period.

The notes on page 11 form part of these consolidated interim financial statements.

Consolidated Interim Statement of Financial Position

Period Ended 31 July 2025

	Group 6 months to 31 July 2025	Group Year ended 31 January 2025	Group 6 months to 31 July 2024
	Unaudited £	Audited £	Unaudited £
Non-Current assets			
Tangible assets	1,263,789	1,364,626	1,466,641
Intangible assets	1,226,406	1,442,550	1,675,182
Investments in subsidiaries	-	-	-
	2,490,195	2,807,176	3,141,823
Current assets			
Cash and cash equivalents	612,976	1,664,098	48,017
Trade and other receivables	92,158	152,310	69,724
Receivables due in more than one year	-	3,971	-
	705,134	1,820,379	117,741
Current liabilities			
Trade and other payables	2,056,830	1,712,738	3,388,129
Convertible loan notes	793,680	737,781	685,005
	2,850,510	2,450,519	4,073,134
Non-Current liabilities			
Convertible loan notes	-	-	-
Deferred tax liability	49,436	49,436	46,739
Total assets less liabilities	295,383	2,127,600	(860,309)
Capital and reserves			
Share capital	8,598,293	8,598,293	5,756,057
Share premium	6,771,545	6,771,545	5,328,996
Share option reserve	1,320,328	1,201,026	50,015
Currency translation reserve	3,768	984	-
Retained deficit	(16,398,551)	(14,444,248)	(11,995,377)
Total equity and liabilities	295,383	2,127,600	(860,309)

The consolidated interim financial statements were approved and authorised for issue by the Board and were signed on its behalf by:

Melissa Sturgess
Chief Executive Officer
13 October 2025

The notes on page 11 form part of these consolidated interim financial statements.

Consolidated Interim Statement of Changes in Equity

Period Ended 31 July 2025

GROUP	Share Capital	Share Premium	Share Option Reserve	Retained Earnings	Currency translation reserve	Total
	£	£	£	£	£	£
As at 1 February 2025	8,598,293	6,771,545	1,201,026	(14,444,248)	984	2,127,600
Total comprehensive loss for the period	-	-	-	(1,954,303)	-	(1,954,303)
Currency translation differences	-	-	-	-	2,784	2,784
Share based payment	-	-	119,302	-	-	119,302
Balance at 31 July 2025	8,598,293	6,771,545	1,320,328	(16,398,551)	3,768	295,383

GROUP	Share Capital	Share Premium	Share Option Reserve	Retained Earnings	Currency translation reserve	Total
	£	£	£	£	£	£
As at 1 February 2024	5,756,057	5,328,996	48,398	(10,782,107)	-	351,344
Total comprehensive loss for the year	-	-	-	(3,662,141)	-	(3,662,141)
Proceeds from share issue	2,842,236	1,442,549	-	-	-	4,284,785
Currency translation differences	-	-	-	-	984	984
Issue of share options	-	-	1,152,628	-	-	1,152,628
Balance at 31 January 2025	8,598,293	6,771,545	1,201,026	(14,444,248)	984	2,127,600

GROUP	Share Capital	Share Premium	Share Option Reserve	Retained Earnings	Currency translation reserve	Total
	£	£	£	£	£	£
As at 1 February 2024	5,756,057	5,328,996	48,398	(10,782,107)	-	351,344
Total comprehensive loss for the period	-	-	-	(1,213,270)	-	(1,213,270)
Share based payment	-	-	1,617	-	-	1,617
Balance at 31 July 2024	5,756,057	5,328,996	50,015	(11,995,377)	-	(860,309)

Consolidated Interim Statement of Changes in Equity

Period Ended 31 July 2025

The following describes the nature and purpose of each reserve within owners' equity:

Reserve	Description and purpose
Share capital	This represents the nominal value of shares issued.
Share premium	Amount subscribed for share capital in excess of nominal value.
Retained earnings	Cumulative net gains and losses recognised in the statement of comprehensive income.

The notes on page 11 form part of these consolidated interim financial statements.

Consolidated Interim Statement of Changes in Equity

Period Ended 31 July 2025

ACCOUNTING POLICIES

General information

Ananda Pharma Plc's consolidated interim financial statements are presented in British Pound Sterling (GBP) which is the functional currency of the parent company. These consolidated interim financial statements were approved for issue by the Board of Directors on 13 October 2025.

The financial information set out in these interim financial statements does not constitute statutory accounts as defined in Section 434 of the Companies Act 2006. The Company's statutory financial statements for the year ended 31 January 2025 have been filed with the Registrar of Companies. The auditor's report on those financial statements was unqualified and did not contain a statement under Section 498(2) of the Companies Act 2006.

These interim results have not been audited nor have they been reviewed by the Company's auditors under ISRE 2410 of the Auditing Practices Board.

Basis of preparation

These consolidated interim financial statements are for the six-month period ended 31 July 2025. They have been prepared following the recognition and measurement principles of FRS 102. They do not include all the information required for full annual financial statements and should be read in conjunction with the audited consolidated financial statements for the period ended 31 January 2025.

These unaudited consolidated interim financial statements have been prepared on a going concern basis which the Directors believe to be appropriate.

These unaudited consolidated interim financial statements have been prepared in accordance with the accounting policies adopted in the consolidated financial statements for the period ended 31 January 2025.

The principle accounting policies applied in the preparation of these Interim financial statements are the same as those applied in preparation of the group's annual financial statements.

1. Foreign currency transactions

Transactions in foreign currencies are translated to GBP at the exchange rates at the dates of the transactions. Monetary assets and liabilities denominated in foreign currencies at the reporting date are translated to GBP at the exchange rate on that date. Foreign exchange differences arising on translation are recognised in the statement of comprehensive income.

Monetary assets and liabilities denominated in a foreign currency at the statement of financial position date are translated using the year end rate. For the purposes of the consolidation, where an alternative reporting currency is used by a subsidiary, amounts are converted using the year end rate.

2. Earnings per share

The calculation of earnings per share is based on the loss attributable to ordinary shareholders divided by the average number of shares in issue during the period.

Consolidated Interim Statement of Changes in Equity

Period Ended 31 July 2025

SUBSEQUENT EVENTS

Termination of contractor relationship for epilepsy trials

On 26 September 2025, the Company confirmed that it has terminated its relationship with its contractor supplying MRX2 and MRX2T formulations for epilepsy studies at University College London (UCL) and Great Ormond Street Hospital (GOSH). As a result, Ananda has received confirmation that it is no longer involved in these studies. In light of delays and intellectual property constraints in this indication, the Company has resolved to prioritise resources on its lead programme, MRX1, for the treatment of endometriosis and chemotherapy-induced peripheral neuropathy.

Completion of dosing in MRX1 Phase 1 trial

On 6 October, the Company announced that the final participant has received their last dose in its Phase 1 pharmacokinetic, safety and tolerability study of MRX1 in healthy volunteers. The study enrolled 19 participants and dosing is now complete. Data quality review and analysis will follow, with final safety and tolerability results expected in Q4 2025 and final pharmacokinetic results anticipated in Q1 2026.